Rubicon Research IPO
Rubicon Research IPO will open on 09 Oct '25 and close on 13 Oct '25, with the IPO allotment date scheduled for 14 Oct '25. The shares are scheduled to list on NSE with a tentative listing date fixed for 16 Oct '25. The price band is set at ₹461 to ₹485 per share with a minimum lot size of 30 shares.
Free Demat with Zero AMC*
Rubicon Research IPO Subscription Breakdown
| Investory Category | Subscription Percentage | Amount Raised (₹ Crores) |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | 75% | 1,23,41,752.5 crores |
| Non-Institutional Investors (NIIs) | 15% | 24,68,350.5 crores |
| Retail Individual Investors (RIIs) | 10% | 16,45,567 crores |
About Rubicon Research Ltd IPO
Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, and commercialization of differentiated formulations.
As of June 30, 2025, Rubicon Research had a portfolio of 72 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products approved by the US FDA. The company’s portfolio includes 66 commercialized products, with a US generic pharmaceutical market size of USD 2,455.7 million, of which Rubicon Research Limited contributed USD 195 million in Fiscal 2024.
As of June 30, 2025, the company has 17 new products awaiting US FDA ANDA approval and 63 products at various stages of development.
As of June 30, 2025, the company marketed over 350 SKUs to 96 customers, including three major wholesalers who, account for more than 90% of wholesale drug distribution in the US. The company also supplies group purchasing organizations (GPOs), national pharmacy chains, regional pharmacy chains, and managed care organizations.
Beyond the US market, Rubicon Research Limited, directly or through third-party distribution partners, has registered or filed 48 product applications across Australia, the United Kingdom, Singapore, Saudi Arabia, and the United Arab Emirates and expects to commence commercial activities upon approval. The company also provides contract manufacturing services to select customers in India, Australia, and New Zealand.
Rubicon Research Limited operates three manufacturing facilities in India and two US FDA inspected R&D facilities-one each in India and Canada.
Competitive strengths
- Fastest-growing Indian pharmaceutical company amongst peers.
- Data-driven product selection framework
- Strong R&D capabilities
- Robust sales and distribution capabilities in the US
- Strong track record of compliance combined with expertise in cost effective manufacturing
- Experienced and entrepreneurial management team
Rubicon Research IPO Strengths & Weaknesses
No Data Found
Rubicon Research IPO Issue Details
| Issue Composition: | |
|---|---|
| Face Value | ₹0 per share |
| Total Issue Size | 1,64,55,670 shares (aggregating up to ₹14,550 crores) |
| Fresh Issue | NaN shares (aggregating up to To be announced) |
| Offer for Sale | NaN shares of ₹0 (aggregating up to To be announced) |
| Issue Type | |
| Post-Issue Shareholding Pattern: | |
|---|---|
| Pre-Issue Shareholding | shares |
| Post-Issue Shareholding | 0 shares |
Rubicon Research IPO Shares
| Minimum Shares | Maximum Shares |
|---|---|
| -- | -- |
The lot size of Rubicon Research ipo has been designed to ensure broad participation while maintaining optimal price discovery.
How to Apply for Rubicon Research IPO
- Log in to your Choice account
- Select IPO
- Enter the number of lots and your price
- Verify UPI ID
- Complete the transaction on your UPI app
Rubicon Research Lead Manager(s)
| Book Running Lead Manager(s) |
|---|
